Background: BAL4815 (from Basilea Pharmaceutica Ltd) is the active component of the water-soluble azole (WSA) BAL8557, reported to have favorable pharmacokinetics and to be generally well tolerated. We have determined in-vitro activity against yeasts and moulds and quality control ranges for testing by EUCAST procedures. Method: A total of 16 quality control and reference strains were investigated, using the standards for susceptibility testing of fermentative yeasts (document 7.1) and of Aspergillus spp. (in press). Tests were performed in triplicate on three separate days. Data are expressed in Âµg/mL. Analysis between repetitions: (i) Agreement (AGR): discrepancies of no more than two 2X dilutions; (ii) Correlation: intraclass correlation coefficient (ICC), over a maximum value of 1. Results: *Mould Collection of the Spanish National Center for Microbiology (CNM-CM). Conclusions: (i) BAL4815 exhibited good activity against yeast and moulds apart from the multi-resistant organisms C. tropicalis ATCC200956 and S. apiospermum CNM-CM-678. (ii) Reproducibility between repetitions was very high with an overall AGR of 98%. (iii) Correlation was almost perfect with ICC of 0.99.
Full conference title:
46th Interscience Conference on Antimicrobial Agents and Chemotherapy
- ICAAC 46th